344 related articles for article (PubMed ID: 30149056)
21. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
Moyer CL; Phillips R; Deek MP; Radwan N; Ross AE; Antonarakis ES; Reyes D; Wright J; Terezakis SA; Song DY; DeVille C; Walsh PC; DeWeese TL; Carducci M; Schaeffer EM; Pienta KJ; Eisenberger M; Tran PT
World J Urol; 2019 Dec; 37(12):2623-2629. PubMed ID: 30191396
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
Kumar A; Straka C; Courtney PT; Vitzthum L; Riviere P; Murphy JD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1185-1194. PubMed ID: 33002541
[TBL] [Abstract][Full Text] [Related]
25. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.
Palma DA; Haasbeek CJ; Rodrigues GB; Dahele M; Lock M; Yaremko B; Olson R; Liu M; Panarotto J; Griffioen GH; Gaede S; Slotman B; Senan S
BMC Cancer; 2012 Jul; 12():305. PubMed ID: 22823994
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.
Mohamed AA; Goncalves M; Singh BP; Tometten M; Rashad A; Hölzle F; Hackenberg S; Eble M
Strahlenther Onkol; 2024 May; 200(5):400-408. PubMed ID: 38063900
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
Helou J; Thibault I; Poon I; Chiang A; Jain S; Soliman H; Erler D; Yeung L; Cheung P
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):419-427. PubMed ID: 28463162
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
31. Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.
Lehrer EJ; Singh R; Wang M; Chinchilli VM; Trifiletti DM; Ost P; Siva S; Meng MB; Tchelebi L; Zaorsky NG
JAMA Oncol; 2021 Jan; 7(1):92-106. PubMed ID: 33237270
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
33. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
34. Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis.
Lancia A; Ingrosso G; Carosi A; Di Murro L; Giudice E; Cicchetti S; Morelli P; di Cristino D; Bruni C; Murgia A; Cancelli A; Turturici I; Iadevaia A; Ponti E; Santoni R
Acta Oncol; 2017 Nov; 56(11):1621-1625. PubMed ID: 28820285
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
36. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
38. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.
De Rose F; Cozzi L; Navarria P; Ascolese AM; Clerici E; Infante M; Alloisio M; Testori A; Toschi L; Finocchiaro G; Santoro A; Scorsetti M
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):13-20. PubMed ID: 26385822
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
